708-1428

completed

Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
708 (USA) · Dr. Kim
consented 2013-11-09

AEs

Serious

Dropout signal

–

Adverse events

moderate assessed

Moderate APPLICATION SITE ERYTHEMA — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-12-10 (study day 32.0); relationship: PROBABLE

severe assessed

Severe APPLICATION SITE ERYTHEMA — outcome: RECOVERED/RESOLVED; onset 2013-12-10 (study day 32.0); relationship: PROBABLE

moderate assessed

Moderate APPLICATION SITE PRURITUS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-12-10 (study day 32.0); relationship: PROBABLE

severe assessed

Severe APPLICATION SITE PRURITUS — outcome: RECOVERED/RESOLVED; onset 2013-12-10 (study day 32.0); relationship: PROBABLE

moderate assessed

Moderate APPLICATION SITE WARMTH — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-12-10 (study day 32.0); relationship: PROBABLE

severe assessed

Severe APPLICATION SITE WARMTH — outcome: RECOVERED/RESOLVED; onset 2013-12-10 (study day 32.0); relationship: PROBABLE

mild assessed

Mild EPISTAXIS — outcome: RECOVERED/RESOLVED; onset 2013-11-22 (study day 14.0); relationship: REMOTE

Data queries

No data queries.